Please assess the completion status of the following clinical trial:

Trial Title: Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age range 18-45 years~2. DSM-IV diagnosis of cannabis dependence, based on the Structured Clinical Interview for DSM-IV (SCID)~3. DSM-IV diagnosis of schizophrenia or schizoaffective disorder, based on the Structured Clinical Interview for DSM-IV (SCID)~4. express a desire to quit cannabis use within the next 30 days~5. have used cannabis on ≥20 days within the past 30 days (i.e., an average of ≥5 day per week)~6. identify cannabis as their primary drug of abuse; 6) stable on antipsychotic medication for ≥1 month~7. for women of childbearing age, a negative pregnancy test at screening with agreement to use adequate contraception to prevent pregnancy and monthly pregnancy tests~8. consent for us to communicate with their prescribing clinician if one exists~9. furnish the names of 2 locators, who would assist study staff in locating them during the study period~10. live close enough to McLean Hospital to attend study visits~11. plan to stay in the Boston area for the next 3 months~12. are willing and able to sign informed consent.~Exclusion Criteria:~1. Current diagnosis of other drug or alcohol dependence (excluding nicotine)~2. significant cardiac disease as indicated by history or suspected by abnormal ECG or history of cardiac symptoms~3. Positive and Negative Syndrome Scale (PANSS) subscale for positive symptoms of psychosis item \> 3 (moderate) at baseline evaluation~4. current medical condition that could prevent regular study attendance~5. liver function tests \>3 times the upper limit of normal range~6. history of seizure disorder or history of head trauma or CNS insult that could predispose the subject to seizures~7. taking clozapine~8. current suicidal risk~9. bradycardia less than or equal to 50 bpm, supine blood pressure of less than or equal to 100/65, a seated blood pressure of less than or equal to 90/60, or orthostatic change of \>20 systolic or \>10 diastolic on standing, at screening or any pre-dose assessment, or symptoms attributable to low BP (i.e. lightheadedness or dizziness on standing)~10. mental retardation or organic mental disorder~11. currently in a residential treatment setting in which substance use is monitored and restricted, since the restricted access to drugs could represent an important confounding variable~12. pregnant, nursing, or, if a woman of childbearing potential, not using a form of birth control judged by the investigator to be effective~13. concomitant treatment with opioid analgesics, sedative hypnotics, or other known CNS depressants~14. known hypersensitivity to cannabinoids or sesame oil or clonidine~15. disease of the gastrointestinal system, liver, or kidneys that may impede metabolism or excretion of dronabinol~16. inability to read or write in English that would hinder their ability to follow study procedures~17. history of seizures or a family history of seizures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Dronabinol + Clonidine (Type: EXPERIMENTAL): Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).